搜尋結果
2024年3月29日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) and muscle relaxant ®
2022年11月7日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal ® (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) in Asia (9 countries/regions*) to a subs...
2024年5月13日 · October 13, 2023. Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness. March 9, 2023. Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties. February 17, 2023.
2021年6月30日 · For Print June 30, 2021 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO ® (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
2019年7月17日 · For Print July 17, 2019 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that Eisai received New Drug Approval for Eisai’s in-house developed anticancer agent Halaven ® (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an ...
2012年4月2日 · Eisai's news release Eisai and Minophagen Pharmaceutical Conclude License Agreement Concerning the Development and Commercialization of Cutaneous T-Cell Lymphoma Treatment Bexarotene in Asia, Oceania, the Middle East and Eastern Europe, etc. is
Eisai's news release EISAI AND BRISTOL MYERS SQUIBB ENTER INTO GLOBAL STRATEGIC COLLABORATION FOR EISAI’S MORAb-202 ANTIBODY DRUG CONJUGATE is posted. For Print June 18, 2021 Eisai Co., Ltd. Bristol Myers Squibb TOKYO AND ...
